Get the Stockscreener App
54.50
0.52%
0.28
After Hours:
54.50
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $54.50, with a volume of 15.69M.
It is up +0.52% in the last 24 hours and up +0.57% over the past month.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$54.22
Open:
$54.1
24h Volume:
15.69M
Relative Volume:
1.04
Market Cap:
$110.95B
Revenue:
$48.03B
Net Income/Loss:
$6.05B
P/E Ratio:
18.40
EPS:
2.9615
Net Cash Flow:
$15.30B
1W Performance:
-4.42%
1M Performance:
+0.57%
6M Performance:
+16.73%
1Y Performance:
-4.45%
1-Day Range:
$53.55
$54.62
1-Week Range:
$53.55
$57.00
52-Week Range:
$42.52
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
54.50 | 110.38B | 48.03B | 6.05B | 15.30B | 2.9615 |
|
LLY
Lilly Eli Co
|
1,078.52 | 931.97B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
218.01 | 525.73B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
216.15 | 378.29B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
145.11 | 275.50B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
111.11 | 271.66B | 63.90B | 19.05B | 13.05B | 7.5596 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Upgrade | UBS | Neutral → Buy |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
The Best Stocks to Invest $1,000 in Right Now - The Motley Fool
Syngene Extends Research Collaboration with Bristol Myers Squibb till 2035 - Chemical Industry Digest
Big-Pharma Partner Harbour BioMed Boosts Stake In Spruce Biosciences - Benzinga
Leerink Bullish on Bristol-Myers Squibb Company (BMY) Amid Ample Pipeline Optionality in 2026 - Finviz
Bristol-Myers Squibb (BMY) Upgraded to Buy by UBS, Noting a Skewed Risk/Reward Ratio for the Stock - Insider Monkey
Bristol Myers (BMY) Teams Up with Microsoft for Lung Cancer Dete - GuruFocus
BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now? - TradingView — Track All Markets
Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035 - Yahoo Finance
Microsoft (MSFT) and Bristol Myers Squibb (BMY) Partner to Enhan - GuruFocus
Bristol Myers partners with Microsoft for AI-driven lung cancer detection - Reuters
Guggenheim Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $62 - 富途资讯
Bristol Myers partners with Microsoft for AI-driven lung cancer detection By Reuters - Investing.com
Bristol Myers Squibb Partners With Microsoft On AI Lung Cancer Detection - Nasdaq
Bristol Myers Squibb and Microsoft partner to detect lung cancer earlier - Investing.com
Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer - marketscreener.com
Scotiabank Notes Bristol-Myers Squibb Company (BMY) as Appealing Investment in 2026 - Finviz
2 Dividend Stocks to Buy and Hold For 10 Years - Finviz
Syngene expands research collaboration with Bristol Myers Squibb - The Economic Times
Immunai and Bristol Myers Squibb sign AI partnership - jpost.com
Syngene extends Bristol Myers Squibb research partnership till 2035 - scanx.trade
Syngene International Extends Research Partnership With Bristol Myers Squibb Through 2035 - scanx.trade
Bristol-Myers Squibb Co (NYSE:BMY): A High-Yield Dividend Stock With a Path to Growth - Chartmill
2 Top Blue-Chip Stocks to Buy and Hold in 2026 - Morningstar
How Is The Market Feeling About Bristol-Myers Squibb Co? - Benzinga
Novo Nordisk, BioMarin make AI moves; Bristol Myers welcomes neurology exec from Eisai - Endpoints News
Another ADC foray for Bristol Myers Squibb - The Pharma Letter
Campbell & CO Investment Adviser LLC Has $5.81 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
The Bull Case For Bristol-Myers Squibb (BMY) Could Change Following Camzyos’ Phase 3 Adolescent oHCM Win - simplywall.st
Bernstein Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY) - The Globe and Mail
Immunai and Bristol Myers Squibb turn to AI to decode immune responses in clinical trials - CTech
Stephens Inc. AR Raises Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb (NYSE:BMY) Trading 1.9% Higher After Analyst Upgrade - MarketBeat
Rep. Gilbert Ray Cisneros, Jr. Buys Bristol Myers Squibb Company (NYSE:BMY) Shares - MarketBeat
Bristol-Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescent Patients - Finviz
Bristol Says New Version of Opdivo on Track to Meet Target - Bloomberg.com
Leerink Partners Remains a Buy on Bristol-Myers Squibb (BMY) - The Globe and Mail
Manning & Napier Advisors LLC Lowers Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Pharmaceutical research and development pipeline - Bristol Myers Squibb
Leerink Partners Raises Price Target for Bristol-Myers Squibb (BMY) to $60 | BMY Stock News - GuruFocus
Leerink Partners Issues Positive Forecast for Bristol Myers Squibb (NYSE:BMY) Stock Price - MarketBeat
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock - Yahoo Finance
Bristol Myers Squibb Company $BMY Position Raised by Sumitomo Mitsui Trust Group Inc. - MarketBeat
JPM26: BMS places confidence in core pipeline to weather 2030 patent cliff - Pharmaceutical Technology
Bristol-Myers Squibb stock price target raised to $60 from $54 at Leerink - Investing.com
Bristol Myers Squibb Company $BMY Shares Sold by GRIMES & Co WEALTH MANAGEMENT LLC - MarketBeat
JPM26: US biotech’s ‘Sputnik moment,’ Pfizer’s obesity ambitions and Bristol Myers’ big year - BioPharma Dive
AbbVie Becomes Latest To License PD-1xVEGF Bispecific In Growing Field - Citeline News & Insights
JPM26: Bristol Myers CEO to 'cast a broad net' as business development remains a top priority - Fierce Pharma
Scotiabank Raises Bristol-Myers (BMY) PT to $60 Citing Catalyst-Rich 2026 Growth - Finviz
Bristol Myers Squibb CEO Outlines 2030 Growth Strategy Focused on Oncology, Immunology, and Cardiovascular Expansion at JP Morgan Healthcare Conference - geneonline.com
Bristol-Myers Squibb Stock Under Pressure: Is This Deep-Value Pharma Name Finally Near a Turning Poi - AD HOC NEWS
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
2.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):